The record
| Class | immune modulator |
|---|---|
| Also known as | Thymalfasin, Zadaxin, Ta1, Thymosin α1 |
| Chain length | - |
| Molecular weight | 3,108.3 Da |
| Half-life | ~2 hours (range <3 hours) |
| Route | SC |
| Studied for | Hepatitis B/C treatment (approved in 35+ countries), Cancer immunotherapy adjuvant, Vaccine adjuvant, Sepsis treatment, COVID-19 (investigational) |
| Research use | T-cell biology, Immunomodulation studies, Cancer immunotherapy research, Viral infection models |
| What has been shown | Enhanced T-cell function and maturation; Improved viral clearance in hepatitis; Reduced mortality in sepsis; Enhanced vaccine responses |
| How it works | Thymosin alpha-1 is a 28-amino acid immunomodulatory peptide that enhances T-cell function, dendritic cell maturation, and antibody responses. It acts through multiple pathways including TLR9 activation, increasing MHC class I expression, and modulating cytokine production (increases IL-2, IFN-γ, decreases TNF-α). |
| Patent status | various formulation patents |
| Regulatory status | Approved in >35 countries for hepatitis B/C; not FDA approved in US |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- GI Inflammation Modulation (affection, 62%)
- Inflammation Modulation (affection, 67%)
- Anti-biofilm treatment (illness, 30%)
- Antimicrobial applications (illness, 30%)
- Cancer immunotherapy adjuvant (illness, 100%)
- COVID-19 (illness, 100%)
- Hepatitis B/C treatment (illness, 100%)
- Immunomodulation (illness, 30%)
- Sepsis treatment (illness, 100%)
- Sepsis/endotoxemia protection (illness, 30%)
- Vaccine adjuvant (illness, 100%)
- Pain (symptom, 50%)
- Frequent infections (symptom, 100%)
- Swelling or inflammation (symptom, 50%)